Comments on "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders" by Tran and Associates: Reply to Kasper and Kufferle

Journal of Clinical Psychopharmacology

Volumn 18, Issue 4, 1998, Pages 354-356

  Tollefson, Gary D ^a   Tran, Pierre V ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0344132783     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/00004714-199808000-00025     Document Type: Letter

References (20)

1. Beasley CM Jr, Hamilton S, Crawford AM, Dellva M, Tollefson GD, Tran PV, Beuzen J, Olanzapine E003 Study Group. Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
2. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-67.
3. Beasley CM Jr, Tollefson G, Tran PV, Satterlee W, Sanger T, Hamilton S, Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
4. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
5. Peuskens J, Risperidone Study Group. Risperidone in the treatment of chronic schizophrenic patients: an international multicentre double-blind parallel-group comparative study versus haloperidol. Br J Psychiatry 1995;166:712-26.
6. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
7. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
8. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997;17:205-29.
9. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley CM Jr, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
10. Tran PV, Tollefson GD. Reply-letter to the editor. J Clin Psychopharmacol 1998;18:175-6.
11. Beasley CM. Response to letter to the editors. Neuropsychopharmacology 1997:16:89-90.
12. Crawford AMK, Beasley CM Jr, Tollefson GD. The acute and longterm effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54.
13. Tran PV, Tollefson GD. Reply-letter to the editor. J Clin Psychopharmacol 1998;18:177-9.
14. Gutierrez-Esteinou R, Grebb JA. Risperidone: an analysis of the first three years in general use. Int Clin Psychopharmacol 1997;12:S3-S10.
15. Garbe E, Rohmel J, Gundert-Remy U. Clinical and statistical issues in therapeutic equivalence trials. Eur J Clin Pharmacol 1993;45:1-7.
16. 2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine-a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996;124:148-53.
17. 2-Receptor imaging (SPECT) as a tool for measuring the efficacy and side-effect profile of treatment with neuroleptics [abstract]. Biol Psychiatry 1996;39:564.
18. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997;16:1-7.
19. Seeman P. in reply [letter]. Arch Gen Psychiatry 1998;55:284.
20. 2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 1996;153:183-90.